|
| 37931288 | Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma. | Cancer Discov | 2024 |
| 37838086 | Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation. | J Thorac Oncol | 2024 |
| 37976444 | SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. | J Clin Oncol | 2024 |
| 36240971 | Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228. | J Thorac Oncol | 2023 |
| 37808711 | Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma. | bioRxiv | 2023 |
| 37487667 | Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study. | J Immunother Cancer | 2023 |
| 37555284 | Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. | Oncologist | 2023 |
| 37589215 | Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. | Oncologist | 2023 |
| 37795442 | ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy. | Front Oncol | 2023 |
| 37502974 | Tumor-intrinsic LKB1-LIF signaling axis establishes a myeloid niche to promote immune evasion and tumor growth. | bioRxiv | 2023 |
| 37531417 | Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. | Sci Transl Med | 2023 |
| 37425844 | Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancer. | bioRxiv | 2023 |
| 36993643 | Inference of single cell profiles from histology stains with the Single-Cell omics from Histology Analysis Framework (SCHAF). | bioRxiv | 2023 |
| 36951942 | IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. | J Clin Invest | 2023 |
| 37084736 | Genomic mapping of metastatic organotropism in lung adenocarcinoma. | Cancer Cell | 2023 |
| 37182602 | Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification. | J Thorac Oncol | 2023 |
| 37382635 | De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways. | Clin Cancer Res | 2023 |
| 37210008 | Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation. | J Thorac Oncol | 2023 |
| 37001526 | Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. | Cancer Cell | 2023 |
| 37231281 | Breathing room - focusing on the 'other' lung cancer. | Nat Cancer | 2023 |
| 37131623 | <i>In vivo</i> metabolomics identifies CD38 as an emergent vulnerability in <i>LKB1</i> -mutant lung cancer. | bioRxiv | 2023 |
| 37098228 | Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer? | J Clin Oncol | 2023 |
| 37432985 | Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. | Clin Cancer Res | 2023 |
| 37355629 | Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. | J Hematol Oncol | 2023 |
| 37127830 | Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies. | Nat Immunol | 2023 |
| 36889516 | Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis. | Int J Radiat Oncol Biol Phys | 2023 |
| 36871392 | Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. | ESMO Open | 2023 |
| 36574773 | The ectonucleotidase CD39 identifies tumor-reactive CD8<sup>+</sup> TÂ cells predictive of immune checkpoint blockade efficacy in human lung cancer. | Immunity | 2023 |
| 36824957 | CRACD loss promotes small cell lung cancer tumorigenesis via EZH2-mediated immune evasion. | bioRxiv | 2023 |
| 36669791 | Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. | J Immunother Cancer | 2023 |
| 36494075 | Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers. | J Thorac Oncol | 2023 |
| 36307533 | Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. | Nat Rev Clin Oncol | 2023 |
| 34561242 | <i>Smarca4</i> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. | Cancer Discov | 2022 |
| 35584676 | WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. | Cell Rep | 2022 |
| 35477182 | Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 35613997 | Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. | Clin Lung Cancer | 2022 |
| 35613620 | ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. | Mol Cell | 2022 |
| 35440124 | Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. | Nat Commun | 2022 |
| 35767426 | Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. | Clin Cancer Res | 2022 |
| 35704797 | Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. | JCO Precis Oncol | 2022 |
| 35792876 | Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. | Clin Cancer Res | 2022 |
| 35760287 | POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. | J Thorac Oncol | 2022 |
| 35789380 | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | Cancer Discov | 2022 |
| 35759660 | Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. | Proc Natl Acad Sci U S A | 2022 |
| 35691495 | Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. | J Thorac Oncol | 2022 |
| 35361996 | Inferring gene expression from cell-free DNA fragmentation profiles. | Nat Biotechnol | 2022 |
| 35941262 | cfDNA methylome profiling for detection and subtyping of small cell lung cancers. | Nat Cancer | 2022 |
| 36313536 | Protocol to dissociate, process, and analyze the human lung tissue using single-cell RNA-seq. | STAR Protoc | 2022 |
| 36275912 | BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study. | JTO Clin Res Rep | 2022 |
| 36357680 | Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. | Nat Med | 2022 |